Andrew R. Weintraub

Andrew R. Weintraub

Auto-generated profile, based on publicly available information

Andrew R. Weintraub

CardioVascular Center, Tufts Medical Center, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2023 in ASAIO Journal
Verified
Journal Article
Closed access
DPDavid Posawatz
David Posawatz
JBJoshua Bloom
Joshua Bloom
AMAlison Massed
Alison Massed
ACAbhishek Chatterjee
Abhishek Chatterjee
CRCharles Resor
Charles Resor
MKMasashi Kawabori
Masashi Kawabori
Transcatheter aortic valve replacement (TAVR) has become the preferred treatment for severe aortic stenosis. Previous studies compare clinical outcomes of leading TAVR valves, but there is no evidence of cost-utility comparison, leaving a clinical information gap when selecting valves. Here we share a cost-utility analysis comparing the Sapien 3 (S3) (Edwards Lifesciences, Irvine, CA) and CoreValve Evolut R (ER) (Medtronic, Dublin, IR) across five clinical endpoints. Utility scores from patient surveys and clinical outcomes from the literature were used to estimate quality-adjusted life years (QALYs) associated with successful procedure and postoperative complications for S3 and ER. A decision tree was constructed with rollback analysis to highlight the more cost-effective strategy. An incremental cost-utility ratio (ICUR) analysis was performed with a willingness to pay at $50,000. Deterministic and probabilistic sensitivity analyses were performed to validate robustness of results and account for uncertainty. S3 was found to be more costly ($68,377 vs. $66,072), but more effective (1.87 vs. 1.66) compared with ER. An ICUR of 11,288.12 favored S3, making it the more cost-effective option with a moderate confidence of 73.68% in Monte Carlo analysis. Cost-utility analysis can be used to aid in healthcare economics decision-making when selecting between comparable technologies used for TAVR procedures.

1 October 1990 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AWAndrew R. Weintraub
Andrew R. Weintraub
Antonis S ManolisAntonis S Manolis
Antonis S Manolis
NEN.A.MArk Estes
N.A.MArk Estes

1 September 2020 in Journal of the American Society of Echocardiography
Verified
Journal Article
Open access
PDF file
NHNisha Hosadurg
Nisha Hosadurg
BKBenjamin Koethe
Benjamin Koethe
DHDou Huang
Dou Huang
AWAndrew R. Weintraub
Andrew R. Weintraub
APAyan R. Patel
Ayan R. Patel
BWBenjamin S. Wessler
Benjamin S. Wessler
Paradoxical low-flow low-gradient aortic stenosis (P-LFLG AS) is a high-risk yet incompletely understood subset of severe AS, Hachicha Z. Dumesnil J.G. Bogaty P. Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation. 2007; 115 : 2856-2864 Google Scholar for which studies have not uniformly noted improved outcomes after aortic valve replacement. Eleid M.F. Sorajja P. Michelena H.I. Malouf J.F. Scott C.G. Pellikka P.A. Flow-gradient patterns in severe aortic stenosis with preserved ejection fraction. Circulation. 2013; 128 : 1781-1789 Google Scholar , Mohty D. Magne J. Deltreuil M. Aboyans V. Echahidi N. Cassat C. et al. Outcome and impact of surgery in paradoxical low-flow, low-gradient severe aortic stenosis and preserved left ventricular ejection fraction: a cardiac catheterization study. Circulation. 2013; 128 : S235-S242 Google Scholar Several vascular, valvular, and myocardial conditions contribute to low transvalvular flow (LF) across stenosed aortic valves. Annabi M.S. Clisson M. Clavel M.A. Pibarot P. Workup and management of patients with paradoxical low-flow, low-gradient aortic stenosis. Curr Treat Options Cardiovasc Med. 2018; 20 : 49 Google Scholar The cumulative burden of LF conditions may affect hemodynamic improvement after transcatheter aortic valve replacement (TAVR) and explain the aforementioned varying survival benefits. In this cohort of P-LFLG AS patients who underwent TAVR, we assessed whether the cumulative burden of LF conditions present at the time of TAVR was associated with change in indexed stroke volume (SVi) post-TAVR.